Cell Processing and Storage, core will support this grant proposal by providing four specific functions. First, for which funding is not requested, this core will provide the critical instrumentation and technical expertise in cell procurement and the processing of clinical components necessary to support the transplantation studies. Second, the Core will characterize the allogeneic bone marrow and peripheral blood stem cell PBSC) components utilized by quantitative flow cytometry for T, B, NK, dendritic cell, and progenitor cell activity, and also for in vitro colony-forming capacity. These data will be useful in determining which specific cell populations and lineages may be correlated with specific clinical outcomes. This will in turn help to stimulate the development of novel graft engineering approaches and techniques that could improve future allogeneic stem cell transplantation studies. Third, the Core will establish and operate a Repository of Research Specimens. This Repository will consist of multiple aliquots of blood and/or bone marrow samples, DNA preparations, and established B-LCL lines obtained from Fred Hutchinson Cancer Research Center (FHCRC) transplant patients and normal donor controls. These samples will be extremely useful in helping to define the mechanisms involved in engraftment, disease control, immune reconstitution, and graft-versus-host disease. Fourth, this core will assist in the development of novel and improved clinical cell processing techniques for the therapeutic cGMP production of antigen-specific T cells and for research cell selections as part of the pharmacology studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018029-27
Application #
6618821
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-03-18
Project End
2006-11-30
Budget Start
Budget End
Support Year
27
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications